Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fractyl HealthGUTS +1.15%11 Current Ratio is 4.28 as of Mar. 2026, which is at its 10-year median of 4.28. GuruFocus rates GUTS with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,410 Biotechnology companies, Fractyl Health ranks better than 53.05% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Fractyl Health's current ratio for the quarter that ended in Mar. 2026 was 4.28.
Fractyl Health has a current ratio of 4.28. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Fractyl Health's Current Ratio or its related term are showing as below:
GUTS'
s Current Ratio Range Over the Past 10 Years
Min: 1.22 Med: 4.28 Max: 9.38
Current: 4.28
During the past 7 years, Fractyl Health's highest Current Ratio was 9.38. The lowest was 1.22. And the median was 4.28.
GUTS's Current Ratio is ranked better than 53.05% of 1410
companies
in the Biotechnology industry
Industry Median: 3.87
vs GUTS: 4.28
Fractyl Health (NAS:GUTS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Fractyl Health Current Ratio Related Terms
Fractyl Health Current Ratio Historical Data
* Premium members only.
The historical data trend for Fractyl Health's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GUTS vs ENGN, ANIX, VTVT: Current Ratio Comparison
For the Biotechnology subindustry, Fractyl Health's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fractyl Health Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fractyl Health's Current Ratio distribution charts can be found below:
* The bar in red indicates where Fractyl Health's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fractyl Health (GUTS) has a Current Ratio of 4.28 as of Mar. 2026. This is near median its historical median of 4.28. Over the past decade, Fractyl Health's Current Ratio has ranged from 1.22 to 9.38. According to the industry distribution chart, Fractyl Health ranks #662 out of 1410 companies in the Biotechnology industry, placing it in the top 47%.
Is Fractyl Health's Current Ratio too high?
Fractyl Health's current Current Ratio of 4.28 is near median its 10-year median of 4.28. Over the past 10 years, this metric has ranged from a low of 1.22 to a high of 9.38. The Biotechnology industry median Current Ratio is 3.87. Fractyl Health's value of 4.28 is 10.6% above this industry median. Based on the distribution chart, Fractyl Health ranks #662 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fractyl Health has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Fractyl Health's Current Ratio compare to ENGN and ANIX?
According to the Biotechnology industry distribution chart, Fractyl Health ranks #662 out of 1410 companies for Current Ratio. This puts Fractyl Health in the upper half of its industry. The industry median Current Ratio is 3.87. Fractyl Health's value of 4.28 is 10.6% above this benchmark. Historically, Fractyl Health's own Current Ratio has ranged from 1.22 to 9.38 over the past decade. While the company's 10-year median is 4.28 vs. the industry median of 3.87, Fractyl Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.87, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fractyl Health's current Current Ratio of 4.28 is 10.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fractyl Health's current Current Ratio is 4.28, which is near median its own 10-year median of 4.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fractyl Health stock overvalued right now?
Fractyl Health (GUTS) has a current Current Ratio of 4.28. The current Current Ratio is 4.28, which is near median its 10-year median of 4.28 and 10.6% above the Biotechnology industry median of 3.87. Fractyl Health's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Fractyl Health (GUTS), the current Current Ratio is 4.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
11GF Score
Get the complete analysis for GUTS
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GUTS has been successfully added to your 
